Home / Publications / Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties

Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties

Maria Petrovna Paramonova 1
Maria Petrovna Paramonova
, 
Anastasia Lvovna Khandazhinskaya 2
Anastasia Lvovna Khandazhinskaya
, 
Katherine L Seley-Radtke 3
Katherine L Seley-Radtke
, 
Mikhail Stanislavovich Novikov 1
Mikhail Stanislavovich Novikov
10.1016/j.mencom.2017.01.027
Published 2016-12-29
Communication , Volume 27, Issue 1, 85-87
7
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Paramonova M. P. et al. Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties // Mendeleev Communications. 2016. Vol. 27. No. 1. pp. 85-87.
GOST all authors (up to 50) Copy
Paramonova M. P., Khandazhinskaya A. L., Seley-Radtke K. L., Novikov M. S. Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties // Mendeleev Communications. 2016. Vol. 27. No. 1. pp. 85-87.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2017.01.027
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2017.01.027
TI - Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties
T2 - Mendeleev Communications
AU - Paramonova, Maria Petrovna
AU - Khandazhinskaya, Anastasia Lvovna
AU - Seley-Radtke, Katherine L
AU - Novikov, Mikhail Stanislavovich
PY - 2016
DA - 2016/12/29
PB - Mendeleev Communications
SP - 85-87
IS - 1
VL - 27
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2016_Paramonova,
author = {Maria Petrovna Paramonova and Anastasia Lvovna Khandazhinskaya and Katherine L Seley-Radtke and Mikhail Stanislavovich Novikov},
title = {Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties},
journal = {Mendeleev Communications},
year = {2016},
volume = {27},
publisher = {Mendeleev Communications},
month = {Dec},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2017.01.027},
number = {1},
pages = {85--87},
doi = {10.1016/j.mencom.2017.01.027}
}
MLA
Cite this
MLA Copy
Paramonova, Maria Petrovna, et al. “Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties.” Mendeleev Communications, vol. 27, no. 1, Dec. 2016, pp. 85-87. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2017.01.027.

Abstract

The title compounds were prepared from 1-[5-(4-bromophenoxy) pentyl]uracil by the introduction of N-arylacetamide moiety at the 3-position, the better approach involving the use of N-aryl-2-chloroacetamides as the reactants. Antiviral activity of the obtained compounds was estimated.

References

1.
Seroprevalence of Cytomegalovirus Infection in the United States, 1988-1994
Staras S.A., Dollard S.C., Radford K.W., Flanders W.D., Pass R.F., Cannon M.J.
Clinical Infectious Diseases, 2006
2.
Cytomegalovirus
Griffiths P.D., Walter S.
Current Opinion in Infectious Diseases, 2005
3.
Perinatal Cytomegalovirus and Varicella Zoster Virus Infections
Bialas K.M., Swamy G.K., Permar S.R.
Clinics in Perinatology, 2015
4.
Viruses and other infections in stillbirth: what is the evidence and what should we be doing?
Rawlinson W.D., Hall B., Jones C.A., Jeffery H.E., Arbuckle S.M., Graf N., Howard J., Morris J.M.
Pathology, 2008
5.
Congenital Cytomegalovirus Infection
Swanson E.C., Schleiss M.R.
Pediatric Clinics of North America, 2013
7.
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature
Chawla J.S., Ghobadi A., Mosley J., Verkruyse L., Trinkaus K., Abboud C.N., Cashen A.F., Stockerl-Goldstein K.E., Uy G.L., Westervelt P., DiPersio J.F., Vij R.
Transplant Infectious Disease, 2011
8.
Foscarnet
Chrisp P., Clissold S.P.
Drugs, 1991
9.
Cytomegalovirus
Griffiths P., Lumley S.
Current Opinion in Infectious Diseases, 2014
11.
Cidofovir in the Treatment of Cytomegaloviral Disease
Kendle J.B., Fan-Havard P.
Annals of Pharmacotherapy, 1998
13.
Management of Multidrug-Resistant CMV Infection in Immunocompromised Patients: Case Report of a Heart-Transplant Recipient and Review of the Literature
Deback C., Burrel S., Varnous S., Carcelain G., Conan F., Aït-Arkoub Z., Autran B., Gandjbakhch I., Agut H., Boutolleau D.
Antiviral Therapy, 2015
14.
Toward the discovery of dual HCMV–VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides
Babkov D.A., Khandazhinskaya A.L., Chizhov A.O., Andrei G., Snoeck R., Seley-Radtke K.L., Novikov M.S.
Bioorganic and Medicinal Chemistry, 2015
15.
A highly facile approach to the synthesis of novel 2-(3-benzyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-N-phenylacetamides
Novikov M.S., Babkov D.A., Paramonova M.P., Chizhov A.O., Khandazhinskaya A.L., Seley-Radtke K.L.
Tetrahedron Letters, 2013
16.
Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof
Novikov M.S., Babkov D.A., Paramonova M.P., Khandazhinskaya A.L., Ozerov A.A., Chizhov A.O., Andrei G., Snoeck R., Balzarini J., Seley-Radtke K.L.
Bioorganic and Medicinal Chemistry, 2013